Ohio State biotech spinoff Entrada raises $59M to tackle deadly disease with no other treatment

An Ohio State University spinoff developing a treatment for a deadly mitochondrial disease launched Tuesday in Boston with a $59 million round of venture capital investment. Entrada Therapeutics is using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in the power center of a cell. The Series A investment announced Tuesday is the largest ever for an OSU spinoff, the school said. “Our commitment to…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news